Mahmoud Reza Ashrafi1, Soodeh Salehi1, Reza Azizi Malamiri2, Morteza Heidari1, Seyed Ahmad Hosseini1, Mahboubeh Samiei2, Ali Reza Tavasoli1, Mansoureh Togha3. 1. Paediatrics Centre of Excellence, Department of Paediatric Neurology, Children's Medical Centre, Tehran University of Medical Sciences, Tehran, Iran. 2. Department of Paediatric Neurology, Golestan Medical, Educational, and Research Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 3. Neurology Department, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: dr.togha.m@gmail.com.
Abstract
BACKGROUND: In spite of the high occurrence of migraine headaches in school-age children, there are currently no approved and widely accepted pharmacologic agents for migraine prophylaxis in children. Our previous open-label study in children revealed the efficacy of cinnarizine, a calcium channel blocker, in migraine prophylaxis. A placebo-controlled trial was conducted to demonstrate the efficacy and safety of cinnarizine in the prophylaxis of migraine in children. TRIAL DESIGN: A double-blind, placebo-controlled, parallel-group study conducted in a tertiary medical center in Tehran, Iran. METHODS:Children (5-17 years) who experienced migraines with and without aura, as defined on the basis of 2004 International Headache Society criteria, were recruited into the study. Children were excluded if they had complicated migraine, epilepsy, or a history of use of migraine prophylactic agents. Each participant was randomly assigned to receive cinnarizine (a single 1.5 mg/kg/day dose in children weighing less than 30 kg and a single 50 mg dose in children weighing more than 30 kg, administered at bedtime) or placebo. The frequency, severity, and duration of headaches over the trial period were assessed and adverse effects were monitored. RESULTS: A total of 68 children (34 in each group) with migraine were enrolled and 62 participants completed the study. After 3 months of taking cinnarizine or placebo, children in both groups experienced significantly reduced frequency, severity, and duration of headaches compared with baseline measurements (P < 0.001). However, compared with 31.3% of children in the placebo group, 60% of children in the cinnarizine group reported more than 50% reduction in monthly headache frequency (P = 0.023), suggesting that cinnarizine was significantly more effective than placebo in reducing the frequency of headaches. No serious adverse effects of the medications were observed in the treated children, including no abnormal weight gain or extrapyramidal signs. CONCLUSION: Our results indicate that the use of cinnarizine at doses administered in this study is effective and safe for prophylaxis of migraine headaches in children.
RCT Entities:
BACKGROUND: In spite of the high occurrence of migraine headaches in school-age children, there are currently no approved and widely accepted pharmacologic agents for migraine prophylaxis in children. Our previous open-label study in children revealed the efficacy of cinnarizine, a calcium channel blocker, in migraine prophylaxis. A placebo-controlled trial was conducted to demonstrate the efficacy and safety of cinnarizine in the prophylaxis of migraine in children. TRIAL DESIGN: A double-blind, placebo-controlled, parallel-group study conducted in a tertiary medical center in Tehran, Iran. METHODS:Children (5-17 years) who experienced migraines with and without aura, as defined on the basis of 2004 International Headache Society criteria, were recruited into the study. Children were excluded if they had complicated migraine, epilepsy, or a history of use of migraine prophylactic agents. Each participant was randomly assigned to receive cinnarizine (a single 1.5 mg/kg/day dose in children weighing less than 30 kg and a single 50 mg dose in children weighing more than 30 kg, administered at bedtime) or placebo. The frequency, severity, and duration of headaches over the trial period were assessed and adverse effects were monitored. RESULTS: A total of 68 children (34 in each group) with migraine were enrolled and 62 participants completed the study. After 3 months of taking cinnarizine or placebo, children in both groups experienced significantly reduced frequency, severity, and duration of headaches compared with baseline measurements (P < 0.001). However, compared with 31.3% of children in the placebo group, 60% of children in the cinnarizine group reported more than 50% reduction in monthly headache frequency (P = 0.023), suggesting that cinnarizine was significantly more effective than placebo in reducing the frequency of headaches. No serious adverse effects of the medications were observed in the treated children, including no abnormal weight gain or extrapyramidal signs. CONCLUSION: Our results indicate that the use of cinnarizine at doses administered in this study is effective and safe for prophylaxis of migraine headaches in children.
Authors: Maryam Oskoui; Tamara Pringsheim; Lori Billinghurst; Sonja Potrebic; Elaine M Gersz; David Gloss; Yolanda Holler-Managan; Emily Leininger; Nicole Licking; Kenneth Mack; Scott W Powers; Michael Sowell; M Cristina Victorio; Marcy Yonker; Heather Zanitsch; Andrew D Hershey Journal: Neurology Date: 2019-08-14 Impact factor: 9.910
Authors: Jennifer Y Xie; Milena De Felice; Caroline M Kopruszinski; Nathan Eyde; Justin LaVigne; Bethany Remeniuk; Pablo Hernandez; Xu Yue; Naomi Goshima; Michael Ossipov; Tamara King; John M Streicher; Edita Navratilova; David Dodick; Hugh Rosen; Ed Roberts; Frank Porreca Journal: Cephalalgia Date: 2017-04-04 Impact factor: 6.292
Authors: Omid Yaghini; Neda Hoseini; Mohammad Reza Ghazavi; Vahid Mansouri; Jafar Nasiri; Toktam Moosavian; Mohammad Mehdi Salehi Journal: Adv Biomed Res Date: 2022-05-30
Authors: Cosima Locher; Joe Kossowsky; Helen Koechlin; Thanh Lan Lam; Johannes Barthel; Charles B Berde; Jens Gaab; Guido Schwarzer; Klaus Linde; Karin Meissner Journal: JAMA Pediatr Date: 2020-04-01 Impact factor: 16.193